Rafael Pharmaceuticals announced the initiation of a phase 2 open-label trial in collaboration with University Hospitals Cleveland Medical Center to evaluate the efficacy and safety of investigational drug CPI-613 in combination with modified Folfirinox, or mFFX, in patients with localized borderline and unresectable pancreatic cancer. The primary objective of this study is to determine the potential increase in overall survival when CPI-613 is administered in combination with mFFX and to further assess the safety of the CPI-613+ mFFX combination. Pancreatic adenocarcinoma patients 19-80 years old of both sexes with ECOG performance status 0-1 are eligible for enrollment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.